Otezla’s favorable safety profile offsets its moderate efficacy and drives its uptake in psoriasis.
By Anna Reyes, Analyst
8 July 2016
I am an Immunology & Inflammation analyst at Datamonitor Healthcare, based in the London office. I joined Datamonito...
Read full bio
Otezla’s favorable safety profile has driven strong uptake since its 2014 launch in psoriasis, despite its modest efficacy compared to the well-established biologics. Indeed, Novartis reported that Otezla achieved global sales of $472m in 2015, which key opinion leaders have attributed to the convenience of its strong tolerability and safety profile.
“It has been used a lot because it is easy, there are very few side effects, except for the diarrhea and gastrointestinal side effects that about 1 out of 3 people get in the first month of treatment, but otherwise you do not have to do any laboratory monitoring, so it is easy for the physician. There is no monitoring with it and it is a lot less expensive than the biologics.”
US key opinion leader
|Pooled exposure-adjusted incidence rates from the ESTEEM 1 and 2 trials for Otezla in psoriasis|
|Endpoints||Otezla 52 weeks||Otezla 182 weeks|
|Rate of major cardiac events||0.4||0.5|
|Source: Datamonitor Healthcare’s psoriasis marketed drugs, July 2016; Celgene, 2016|
Datamonitor Healthcare’s Psoriasis: Marketed Drugs provides an in-depth analysis of key marketed drugs for psoriasis across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK), including a comparative evaluation of clinical and commercial drug attributes to determine competitiveness in the marketplace.
Get your free demo of Datamonitor Healthcare today. Simply fill out the form to the right >>>